Shang-Fu Chen

Shang-Fu Chen

Auto-generated profile, based on publicly available information

Shang-Fu Chen

Scripps Research Translational Institute, La Jolla, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2014 in ACS Nano
Verified
Journal Article
Open access
ZKZunfu Ke
Zunfu Ke
MLMillicent Lin
Millicent Lin
JCJie-Fu Chen
Jie-Fu Chen
JCJin-Sil Choi
Jin-Sil Choi
YZYang Zhang
Yang Zhang
HTHsian-Rong Tseng
Hsian-Rong Tseng
Unlike tumor biopsies that can be constrained by problems such as sampling bias, circulating tumor cells (CTCs) are regarded as the “liquid biopsy” of the tumor, providing convenient access to all disease sites, including primary tumor and fatal metastases. Although enumerating CTCs is of prognostic significance in solid tumors, it is conceivable that performing molecular and functional analyses on CTCs will reveal much significant insight into tumor biology to guide proper therapeutic intervention. We developed the Thermoresponsive NanoVelcro CTC purification system that can be digitally programmed to achieve an optimal performance for purifying CTCs from non-small cell lung cancer (NSCLC) patients. The performance of this unique CTC purification system was optimized by systematically modulating surface chemistry, flow rates, and heating/cooling cycles. By applying a physiologically endurable stimulation (i.e., temperature between 4 and 37 °C), the mild operational parameters allow minimum disruption to CTCs’ viability and molecular integrity. Subsequently, we were able to successfully demonstrate culture expansion and mutational analysis of the CTCs purified by this CTC purification system. Most excitingly, we adopted the combined use of the Thermoresponsive NanoVelcro system with downstream mutational analysis to monitor the disease evolution of an index NSCLC patient, highlighting its translational value in managing NSCLC.

14 May 2015 in Cancer
Verified
Journal Article
Open access
PDF file
JCJie‐Fu Chen
Jie‐Fu Chen
HHHao Ho
Hao Ho
JLJake Lichterman
Jake Lichterman
YLYi-Tsung Lu
Yi-Tsung Lu
YZYang Zhang
Yang Zhang
Edwin PosadasEdwin Posadas
Edwin Posadas
BACKGROUND: Although enumeration of circulating tumor cells (CTCs) has shown some clinical value, the pool of CTCs contains a mixture of cells that contains additional information that can be extracted. The authors subclassified CTCs by shape features focusing on nuclear size and related this with clinical information.METHODS: A total of 148 blood samples were obtained from 57 patients with prostate cancer across the spectrum of metastatic states: no metastasis, nonvisceral metastasis, and visceral metastasis. CTCs captured and enumerated on NanoVelcro Chips (CytoLumina, Los Angeles, Calif) were subjected to pathologic review including nuclear size. The distribution of nuclear size was analyzed using a Gaussian mixture model. Correlations were made between CTC subpopulations and metastatic status.RESULTS: Statistical modeling of nuclear size distribution revealed 3 distinct subpopulations: large nuclear CTCs, small nuclear CTCs, and very small nuclear CTCs (vsnCTCs). Small nuclear CTCs and vsnCTC identified those patients with metastatic disease. However, vsnCTC counts alone were found to be elevated in patients with visceral metastases when compared with those without (0.36 ± 0.69 vs 1.95 ± 3.77 cells/mL blood; P<.001). Serial enumeration studies suggested the emergence of vsnCTCs occurred before the detection of visceral metastases.CONCLUSIONS: There are morphologic subsets of CTCs that can be identified by fundamental pathologic approaches, such as nuclear size measurement. The results of this observational study strongly suggest that CTCs contain relevant information regarding disease status. In particular, the detection of vsnCTCs was found to be correlated with the presence of visceral metastases and should be formally explored as a putative blood‐borne biomarker to identify patients at risk of developing this clinical evolution of prostate cancer. Cancer 2015;121:3240–3251. © 2015 American Cancer Society.

19 July 2017 in ACS Nano
Verified
Journal Article
Closed access
SHShuang Hou
Shuang Hou
JCJie-Fu Chen
Jie-Fu Chen
MSMin Song
Min Song
YZYazhen Zhu
Yazhen Zhu
YJYu Jen Jan
Yu Jen Jan
HTHsian-Rong Tseng
Hsian-Rong Tseng

1 December 2017 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
CWCheng-Kai Wang
Cheng-Kai Wang
SYShang-Chih Yang
Shang-Chih Yang
SHShu-Ching Hsu
Shu-Ching Hsu
FCFang-Pei Chang
Fang-Pei Chang
YLYu-Tsen Lin
Yu-Tsen Lin
JLJoyce Jean Lu
Joyce Jean Lu

8 May 2025 in European Heart Journal
Verified
Journal Article
Open access
SLSang Eun Lee
Sang Eun Lee
JJJeong Ho Joo
Jeong Ho Joo
HHHee Sang Hwang
Hee Sang Hwang
SCShang-Fu Chen
Shang-Fu Chen
DEDouglas Evans
Douglas Evans
ATAli Torkamani
Ali Torkamani
Background and Aims: Heart failure (HF) remains a significant clinical challenge due to its diverse aetiologies and complex pathophysiology. The molecular alterations specific to distinct cell types and histological patterns during HF progression are still poorly characterized. This study aimed to explore cell-type- and histology-specific gene expression profiles in cardiomyopathies. Methods: Ninety tissue cores from 44 participants, encompassing various forms of cardiomyopathy and control samples with diverse histological features, were analysed using the GeoMx Whole Human Transcriptome Atlas. Data on cell types, clinical information, and histological features were integrated to examine gene expression profiles in cardiomyopathy. Results: The study characterized the cellular composition of ventricular myocardium and validated the GeoMx platform’s efficiency in compartmentalizing specific cell types, demonstrating high accuracy for cardiomyocytes but limitations for endothelial cells and fibroblasts. Differentially expressed genes, including UCHL1 from cardiomyocytes, were associated with degeneration, while CCL14, ACKR1, and PLVAP from endothelial cells were linked to fibrosis. Multiplex immunohistochemistry and integrative analysis of prior sc/snRNA-seq data identified a PLVAP, ACKR1, and CCL14-positive pro-inflammatory endothelial cell subtype linked to fibrosis in HF. Downregulation of ribosomal proteins in cardiomyocytes was associated with myocyte disarray in hypertrophic cardiomyopathy. Additionally, pronounced inflammatory responses were observed in end-stage HF. Combined histological and clinical analysis identified CRIP3, PFKFB2, and TAX1BP3 as novel contributors to HF pathogenesis. Conclusions: These findings highlight the critical role of cell-enriched and histology-specific transcriptome mapping in understanding the complex pathophysiological landscape of failing hearts, offering molecular insights and potential therapeutic targets for future interventions.

17 March 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
PLPei-Lun Lai
Pei-Lun Lai
HLHsuan Lin
Hsuan Lin
SCShang-Fu Chen
Shang-Fu Chen
SYShang-Chih Yang
Shang-Chih Yang
KHKuo-Hsuan Hung
Kuo-Hsuan Hung
JLJoyce Jean Lu
Joyce Jean Lu
Human mesenchymal stromal/stem cells (MSCs) are multipotent and currently undergoing hundreds of clinical trials for disease treatments. To date, no studies have generated induced MSCs from skin fibroblasts with chemicals or growth factors. Here, we established the first chemical method to convert primary human dermal fibroblasts into multipotent, induced MSC-like cells (iMSCs). The conversion method uses a defined cocktail of small molecules and growth factors, and it can achieve efficient conversion with an average rate of 38% in 6 days. The iMSCs have much higher clonogenicity than fibroblasts, and they can be maintained and expanded in regular MSC medium for at least 8 passages and further differentiated into osteoblasts, adipocytes, and chondrocytes. Moreover, the iMSCs can suppress LPS-mediated acute lung injury as effectively as bone marrow-derived mesenchymal stem cells. This finding may greatly benefit stem cell biology, cell therapy, and regenerative medicine.